MarketLens
Sign Up

Heartflow's Q1 2026 Beat: Is This the Turning Point for HTFL

5 months ago
SHARE THIS ON:

Heartflow's Q1 2026 Beat: Is This the Turning Point for HTFL

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•3 weeks ago

HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System

HeartBeam (NASDAQ:BEAT) received FDA Breakthrough Device Designation for its at-home cardiac assessment tool, a regulatory milestone that could accelerate review and market access for the heart attack...
Stock News•2 months ago

Heartflow Q2 Earnings Call Highlights

Heartflow (NASDAQ: HTFL) reported Q2 revenue of $64.1 million, up 48% year-over-year, driven by growth in Plaque Analysis, durable FFR-CT utilization, and CCTA market expansion.
Stock News•3 months ago

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Heartflow and Iovance Biotherapeutics are compared as healthcare investments for 2026. Heartflow holds 1,450+ accounts in AI diagnostics, while Iovance shows revenue growth from personalized TIL cance...

Breaking News

View All →

Top Headlines

View More →
Stock News•59 minutes ago

Jim Cramer sees major implications from SK Hynix's home-run quarter

Stock News•1 hour ago

Google parent Alphabet tumbles after profit disappoints, warns AI is battering its cash flow

Stock News•1 hour ago

Jim Cramer says these tech giants can weather market turbulence

Stock News•1 hour ago

Alphabet Inc. (GOOG) Misses Q3 Earnings and Revenue Estimates

Stock News•1 hour ago

Alphabet (GOOGL) Q3 Earnings and Revenues Miss Estimates